Different incidences of epigenetic but not genetic abnormalities between Wilms tumors in Japanese and Caucasian children

Cancer Science

Volumn 103, Issue 6, 2012, Pages 1129-1135

  Haruta, Masayuki ^a   Arai, Yasuhito ^b   Watanabe, Naoki ^a   Fujiwara, Yuiko ^a   Honda, Shohei ^a   Ohshima, Junjiro ^a   Kasai, Fumio ^a   Nakadate, Hisaya ^c   Horie, Hiroshi ^c   Okita, Hajime ^c   Hata, Jun Ichi ^c   Fukuzawa, Masahiro ^c   Kaneko, Yasuhiko ^c  

^a SAITAMA CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c Japan Wilms Tumor Study Group JWiTS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CAUCASIAN; CHILD; CTNNB1 GENE; EPIGENETICS; FEMALE; GENE; GENE DELETION; GENE MUTATION; GENETIC DISORDER; GENOME IMPRINTING; HEREDITY; HUMAN; IGF2 GENE; INCIDENCE; INFANT; JAPANESE; LOSS OF IMPRINTING; MAJOR CLINICAL STUDY; MALE; NEPHROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; WT1 GENE; WTX GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ASIAN CONTINENTAL ANCESTRY GROUP; BASE SEQUENCE; BETA CATENIN; CHILD; CHILD, PRESCHOOL; DNA COPY NUMBER VARIATIONS; EPIGENESIS, GENETIC; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENES, WILMS TUMOR; HUMANS; INFANT; INSULIN-LIKE GROWTH FACTOR II; JAPAN; KIDNEY NEOPLASMS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; TUMOR SUPPRESSOR PROTEINS; WILMS TUMOR; WT1 PROTEINS;

EID: 84861705719     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02269.x     Document Type: Article

References (32)

1. Kuroishi T, Takezaki T, Tominaga S, Tajima K. Cancer mortality in Japan (1950-2000). In: Tajima K, Kuroishi T, Ohshima A, eds. Cancer Mortality and Morbidity Statistics: Japan and the World-2004. Tokyo : Japan Scientific Societies Press, 2004; 1-93.
2. Parkin DM, Stiller CA, Draper GJ, Bieber CA. The international incidence of childhood cancer. Int J Cancer 1988; 42: 511-20.
3. Goodman MT, Yoshizawa CN, Kolonel LN. Ethnic patterns of childhood cancer in Hawaii between 1960 and 1984. Br J Cancer 1989; 60: 1758-63.
4. Stiller CA, McKinney PA, Bunch KJ, Bailey CC, Lewis IJ. Childhood cancer and ethnic group in Britain: a United Kingdom children's Cancer Study Group (UKCCSG) study. Br J Cancer 1991; 64: 543-8.
5. Fukuzawa R, Breslow NE, Morison IM et al. Epigenetic differences between Wilms' tumours in white and east-Asian children. Lancet 2004; 363: 446-51.
6. Watanabe N, Nakadate H, Haruta M et al. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor. Genes Chromosom Cancer 2006; 45: 592-601.
7. Fukuzawa R, Anaka MR, Weeks RJ, Morison IM, Reeve AE. Canonical WNT signaling determines lineage specificity in Wilms tumour. Oncogene 2009; 28: 1063-75.
8. Corbin M, de Reyniès A, Rickman DS et al. WNT/beta-catenin pathway activation in Wilms tumors: a unifying mechanism with multiple entries? Genes Chromosom Cancer 2009; 48: 816-27.
9. Haruta M, Arai Y, Sugawara W et al. Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities. Genes Chromosom Cancer 2008; 47: 712-27.
10. Kreidberg JA, Sariola H, Loring JM et al. WT-1 is required for early kidney development. Cell 1993; 174: 679-91.
11. Leighton PA, Ingram RS, Eggenschwiler J, Efstratiadis A, Tilghman SM. Disruption of imprinting caused by deletion of the H19 gene region in mice. Nature 1995; 375: 34-9.
12. Hu Q, Gao F, Tian W et al. Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation. J Clin Invest 2010; 121: 174-83.
13. Koesters R, Ridder R, Kopp-Schneider A et al. Mutational activation of the β-catenin proto-oncogene is a common event in the development of Wilms tumors. Cancer Res 1999; 59: 3880-2.
14. Li CM, Kim CE, Margolin AA et al. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors. Am J Pathol 2004; 165: 1943-53.
15. Maiti S, Alam R, Amos CI, Huff V. Frequent association of beta-catenin and WT1 mutations in Wilms tumors. Cancer Res 2000; 60: 6288-92.
16. Rivera MN, Kim WJ, Wells J et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 2007; 315: 642-5.
17. Major MB, Camp ND, Berndt JD et al. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science 2007; 316: 1043-6.
18. Ruteshouser EC, Robinson SM, Huff V. Wilms tumor genetics: mutations in WT1, WTX, and CTNNB1 account for only about one-third of tumors. Genes Chromosom Cancer 2008; 47: 461-70.
19. Perotti D, Gamba B, Sardella M et al. Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors. Oncogene 2008; 27: 4625-32.
20. Wegert J, Wittmann S, Leuschner I, Geissinger E, Graf N, Gessler M. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact. Genes Chromosom Cancer 2009; 48: 1102-11.
21. Nannya Y, Sanada M, Nakazaki K et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 2005; 65: 6071-9.
22. Yamamoto G, Nannya Y, Kato M et al. Highly sensitive method for genome wide detection of allelic composition in nonpaired, primary specimens by use of Affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 2007; 81: 114-26.
23. Warburton PE, Greig GM, Haar T, Willard HF. PCR amplification of chromosome specific alpha satellite DNA: definition of centromeric STS markers and polymorphic analysis. Genomics 1991; 11: 324-33.
24. Kim MK, Min DJ, Rabin M, Licht JD. Functional characterization of Wilms tumor-suppressor WTX and tumor-associated mutants. Oncogene 2010; 320: 832-42.
25. Rivera MN, Kim WJ, Wells J et al. The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Proc Natl Acad Sci USA 2009; 106: 8338-43.
26. Park S, Bernard A, Bove KE et al. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms tumour. Nat Genet 1993; 5: 363-7.
27. Ohlsson R, Cui H, He L et al. Mosaic allelic insulin-like growth factor 2 expression patterns reveal a link between Wilms tumorigenesis and epigenetic heterogeneity. Cancer Res 1999; 59: 3889-92.
28. Yuan E, Li CM, Yamashiro DJ et al. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors. Mol Cancer Res 2005; 3: 493-502.
29. Cerrato F, Sparago A, Verde G et al. Different mechanisms cause imprinting defects at the IGF2/H19 locus in Beckwith-Wiedemann syndrome and Wilms' tumour. Hum Mol Genet 2008; 17: 1427-35.
30. Sasaki K, Soejima H, Higashimoto K et al. Japanese and North American/European patients with Beckwith-Wiedemann syndrome have different frequencies of some epigenetic and genetic alterations. Eur J Hum Genet 2007; 15: 1205-10.
31. Devaskar SU, Raychudhuri S. Epigenetics: a science of heritable biological adaptation. Pediatr Res 2007; 61: 1R-4R.
32. Waterland RA, Lin JR, Smith CA, Jirtle RL. Post-weaning diet affects genomic imprinting at the insulin-like growth factor 2 (Igf2) locus. Hum Mol Genet 2006; 15: 705-16.